Get the latest Moderna (MRNA) stock analysis: balanced risk-reward, new vaccine launches, and pipeline insights. See why we ...

With President Donald Trump back in the White House in 2025, it’s no surprise that he dominates the FactCheck.org year-end ...

A Stanford-led study probes why a very small number of people develop heart inflammation shortly after mRNA COVID-19 ...

Researchers at MIT have unveiled a way to temporarily reboot aging immune systems, using a targeted mRNA therapy that turns ...

The era of CureVac as an independent, publicly traded company has drawn to a close. BioNTech SE has successfully completed ...

The agency’s high-level turnover and conflicting policy decisions on drug oversight have fueled concerns about the leadership ...

Every major pharmaceutical breakthrough in the past 40 years started with taxpayer-funded basic research: mRNA vaccines, ...

Can the weakened immune systems of older individuals be rejuvenated? Researchers from the German Cancer Research Center (DKFZ ...

Moderna Inc. will get as much as $54.3 million for a late-stage trial of its bird flu vaccine in a sign of how outside groups ...

The Coalition for Epidemic Preparedness Innovations said it will invest $54.3 million with Moderna to fund a Phase 3 trial of ...

The Cybertruck, sycophantic AI, and humanoid robots all made this year’s list of the biggest technology failures.

Can the weakened immune systems of older individuals be rejuvenated? Researchers from the German Cancer Research Center (DKFZ ...